Analyst Research

Report Title Price
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Array Biopharma Inc Issues FY 2013 EPS Guidance Below Analysts' Estimates; Issues Q1 2013 Mixed Guidance-Conference Call


Tuesday, 14 Aug 2012 09:00am EDT 

Array Biopharma Inc announced that it is targeting loss per share (EPS) to be $0.60 for fiscal 2013. For the first quarter of 2013, the Company expects revenue to be approximately $17 million and loss per share about $0.15. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report EPS of $(0.51) for fiscal 2013; and revenue of $15 million and EPS of $(0.14) for the first quarter of 2013. 

Company Quote

4.06
 +0.00%
12:01pm EDT